Povital role of platelet count in platelet–lymphocyte count used in distinguishing patients with significant liver fibrosis and insulin resistance

2018 ◽  
Vol 30 (7) ◽  
pp. 807
Author(s):  
Fatih Ozcelik ◽  
Erdim Sertoglu
Keyword(s):  
Insulin Resistance ◽  
Platelet Count ◽  
Liver Fibrosis ◽  
Lymphocyte Count ◽  
Significant Liver Fibrosis

Evaluation of prognostic role of inflammatory index in glioblastoma multiforme patients undergoing to concomitant radio-chemotherapy.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13549-e13549
Author(s):  
Valentina Fausti ◽  
Flavia Foca ◽  
Nada Riva ◽  
Alberto Bongiovanni ◽  
Lorena Gurrieri ◽  
...  
Keyword(s):  
Platelet Count ◽  
Glioblastoma Multiforme ◽  
Neutrophil Count ◽  
Lymphocyte Count ◽  
Statistical Significance ◽  
Prognostic Role ◽  
P Values ◽  
Inflammatory Index ◽  
Radio Chemotherapy

e13549 Background: Hematologic markers of inflammation have been shown to be prognostic in different malignancies. Also in glioblastoma multiforme (GBM) a prognostic role has been demonstrated. The purpose of this study is to evaluate retrospectively the prognostic role of these markers in patients receiving a concomitant radio-chemotherapy after surgery. Methods: Sixty-five GBM patients have been treated with concomitant radio-chemotherapy after surgery at our institute from 2008 to 2017. Information on blood counts were carried out the day before starting therapy and after the day before the last cycle of chemotherapy. Neutrophil/lymphocyte ratio (NLR) and Platelet/lymphocyte ratio (PLR) were computed as the ratio of the absolute neutrophil count and absolute platelet count by the absolute lymphocyte count respectively. Systemic Inflammatory Index (SII) was calculated as platelet count × neutrophil count/lymphocyte count. The optimal cut-point was obtained using X-tile software version 3.6.1. Results: NLR and PLR baseline value didn’t show a statistic a statistically significant prognostic role in PFS or OS. Patients with baseline SII < 480 showed both better PFS and OS (OS: 22.1 VS 11.8 mo p-values 0.0516; PFS: 10.6 VS 5.7 mo p-values 0.0351). Patients aged < 60 years showed better PFS and OS. (PFS 10.3 VS 5.5 p-values 0.0501; OS: 20.6 VS 11.2 mo p-values 0.0124). Statistical significance for SII and age was maintained for both PFS and OS in multivariate analysis as shown in Table 1. Baseline values of NLR PLR and SII have also been correlated with the best response and ORR without showing statistical significance. Conclusions: This restorative study confirms the prognostic value of inflammatory indices in patients with GBM. Correlation analysis with the methylation status of MGMT is ongoing.[Table: see text][Table: see text]

scholarly journals LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB

2021 ◽  
Vol 8 ◽  
Author(s):  
Honghai Xu ◽  
Xutong Li ◽  
Zihao Wu ◽  
Linyan Zhao ◽  
Jiapei Shen ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Operating Characteristic ◽  
Characteristic Curve ◽  
Training Group ◽  
Validation Group ◽  
Severe Liver ◽  
Fibrosis Progression ◽  
Advanced Liver Fibrosis ◽  
Significant Liver Fibrosis

Chronic hepatitis B (CHB) patients with severe liver fibrosis would be more likely to progress to a poorer prognosis. Treatment is considered once the liver fibrosis reaches significant liver fibrosis (≥S2). Leukocyte cell-derived chemotaxin-2 (LECT2) has been shown to contribute to liver fibrosis progression. No research has focused on the role of LECT2 in liver fibrosis in CHB patients. This study enrolled 227 CHB patients and divided them into the training group (n = 147) and validation group (n = 80), respectively. The expression of LECT2 in serum, protein and mRNA of the human liver tissues was detected to analyze the possible associations between LECT2 and liver fibrosis. A receiver operating characteristic curve (ROC) was used to estimate the efficacy of LECT2 for predicting liver fibrosis. The data showed that there was a positive relationship between LECT2 and the progression of liver fibrosis. In the training group, LECT2 was demonstrated to have better effectiveness than APRI and FIB-4. The AUC was 0.861, 0.698, and 0.734 for significant liver fibrosis, and 0.855, 0.769, and 0.752 for advanced liver fibrosis. Besides, the efficacy of LECT2 in different statuses of patients with CHB was examined and the effectiveness of LECT2 had also been confirmed in the validation group. All the results confirmed that LECT2 could act as a perfect predictor and thus offers a novel and direct biomarker to estimate liver fibrosis more accurately.

Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance

2010 ◽  
Vol 18 (1) ◽  
pp. 11-16 ◽  
Author(s):  
F. Blanco ◽  
P. Barreiro ◽  
P. Ryan ◽  
E. Vispo ◽  
L. Martín-Carbonero ◽  
...  
Keyword(s):  
Risk Factors ◽  
Insulin Resistance ◽  
Liver Fibrosis ◽  
Antiretroviral Drugs ◽  
Advanced Liver Fibrosis
Sign in / Sign up

Export Citation Format

Share Document